Apple Takes on the U.S. Ban Over Its Watch’s Blood‑Oxygen Feature
Apple has just stepped into the federal appeals court to fight a 2023 ruling that blocks the import of the Apple Watch Ultra 2 and Apple Watch Series 9. The decision comes from the International Trade Commission (ITC) after Masimo, a company that makes pulse‑oximetry gear, accused Apple of infringing several patents.
The Crux of the Dispute
- Patent Infringement Claim – Masimo alleged that Apple’s blood‑oxygen sensor tech was too close to its own patented designs.
- Market‑Ready Status – Apple’s lawyers argued the watches weren’t “market ready” when Masimo filed the complaint, so the courts shouldn’t rely on hypothetical products to impose trade restrictions.
- No Direct Competition – Apple pointed out that Masimo had no competing product available at the time, making the ruling feel a bit unjustified.
What Apple Stated
During the hearing, Apple opened the floor to the Justice Department, stressing that the ban seemed “unjustified.” The company emphasized that any restrictions should base on real, commercial products, not imagined ones.
Why This Matters
For consumers, it means potential delays in getting the newest Apple Watches into the U.S. market. For tech enthusiasts, it underscores how patents can slow down innovation when two sides feed the same sensor technology.
Bottom Line
If the appeals court sides with Apple, the ban could be overturned, allowing the Ultra 2 and Series 9 to roll out as planned. If it doesn’t, we might see a New England‑style patch: Apple’s tech stuck aside while other companies keep ticking their time.
Masimo’s Legal Take on Apple’s Argument
Masimo’s attorneys claimed that Apple was essentially rewriting the legal rule. They pointed out that Apple insisted the court’s decision should only stick if a product had already hit the market. The case is still pending, with a decision expected before the year ends.
Key Points
- Apple’s Position: The ruling applies only to commercialized gear.
- Masimo’s Counter: Treating it as a rewrite of existing law.
- Current Status: A response is awaited later this year.
